CAR T-Cell Therapy Clinical Trial Landscape for Non-Hodgkin Lymphoma Expands with Over 70 Companies Developing Next-Gen Treatments

September 13, 2026

GlobeNewswire Global

Overview

A report by DelveInsight, released via GlobeNewswire, offers a detailed analysis of the CAR T-cell therapy clinical trial landscape for Non-Hodgkin Lymphoma (NHL). The report highlights over 70 companies advancing next-generation therapies, providing critical insights into key trends, novel treatments, competitive dynamics, major pharma strategies, trial benchmarks, partnerships, licensing activities, and FDA/EMA regulatory pathways.

In Depth

This article provides an overview of a market research report published by DelveInsight via GlobeNewswire.

Report Overview

The “CAR T-Cell Therapy Clinical Trial Status in Non-Hodgkin Lymphoma (NHL)” report, published by DelveInsight, offers a comprehensive analysis of the evolving clinical trial landscape for CAR T-cell therapies targeting Non-Hodgkin Lymphoma. This report details the current situation where over 70 companies are actively developing next-generation treatments in this field, providing valuable insights into the latest research trends, key competitive players, and market entry strategies.

Key Findings

The key findings of the report are as follows:

Expanding Clinical Trial Ecosystem: Non-Hodgkin Lymphoma remains one of the most active areas for CAR T-cell therapy development, with a large number of clinical trials underway. Over 70 companies are engaged in developing therapies using diverse CAR constructs, target antigens, and manufacturing platforms.
Diversification of Novel Therapies: Current research is focused on new approaches to overcome the limitations of existing CAR T-cell therapies (e.g., toxicity, durability, applicability to solid tumors). This includes allogeneic CAR T-cells, TCR therapies, in vivo CAR T-cells, and more advanced gene editing technologies.
Competitive Landscape and Corporate Strategies: Major pharmaceutical and biotechnology companies are strengthening their market positions through partnerships, licensing agreements, and M&A amidst intense competition. There is a clear emphasis on portfolio diversification and investment in novel therapeutic modalities.
Insights into Regulatory Pathways: The analysis of regulatory pathways for the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) provides critical information on approval processes, expedited review designations, and market access strategies. Regulatory bodies are seeking frameworks to quickly deliver innovative therapies to patients while ensuring both safety and efficacy.

About the Publisher

DelveInsight is a company that provides pharmaceutical market research, consulting, and data analytics services. It offers specialized insights into disease epidemiology, pipeline analysis, competitive intelligence, and market forecasts to clients in the pharmaceutical and biotechnology industries.

Source: https://www.globenewswire.com/news-release/2026/09/10/3359869/0/en/car-t-cell-therapy-for-nhl-clinical-trial-landscape-expands-over-70-companies-advancing-next-generation-therapies-delveinsight.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.